Analgesic Efficacy of Transcutaneous Electrical Nerve Stimulation and Dexketoprofen in Renal Colic

ConditionRenal Colic
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorAdiyaman University Research Hospital

About this trial

The aim of this study was to compare the analgesic efficacy of transcutaneous electrical nerve stimulation (TENS) and dexketoprofen trometamol in patients presenting to the emergency department due to renal colic.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

Patients who refuse to participate in the study

Pregnant women

Breastfeeding women

Haemodynamically unstable

Trial design

Design model

Parallel

Treatments tested in this trial

  • TENS

    Device

    Transcutaneous electrical nerve stimulation (TENS) treatment will be activated + NS IV Infusion 100 ml

  • Dexketoprofen Trometamol

    Drug

    50 mg dexketoprofen trometamol in 100 ml normal saline solution + Transcutaneous electrical nerve stimulation treatment will not be activated.

Treatment groups

128 Participants
are divided into 2 treatment groups
Group A: Real Transcutaneous electrical nerve stimulation (TENS)Experimental treatment 1 intervention
Group B: dexketoprofen trometamolActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change of the intensity of pain

Pain intense will be measured by 100 mm visual analog scale (Zero; no pain and 100 mm; the worst pain) after 15th and 30th minutes later the administration of the study interventions

Time frame
15 minutes and 30 minutes after the administration of the study interventions

Secondary outcomes

1

Adverse events

30 minutes after the administration of the study interventions

Time frame
30 minutes after
2

need to rescue medication

30 minutes after the administration of the study interventions

Time frame
30 minutes after

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: